PRODUCT INFORMATIO



Melanocyte-Stimulating Hormone Release-Inhibiting

Factor

н

(trifluoroacetate salt)

Item No. 24476

Formal Name: Synonyms: MF:	L-prolyl-L-leucyl-glycinamide, trifluoroacetate salt MIF-1, MSH-R-IF C ₁₃ H ₂₄ N ₄ O ₃ • XCF ₃ COOH	
FW:	284.4	Ň N N
Purity:	≥95%	
Supplied as:	A lyophilized powder	
Storage:	-20°C	
Stability:	≥4 years	• XCF ₃ COOH
Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.		

Laboratory Procedures

Melanocyte-stimulating hormone release-inhibiting factor (MSH-R-IF) (trifluoroacetate salt) is supplied as a lyophilized powder. A stock solution may be made by dissolving the MSH-R-IF (trifluoroacetate salt) in water. The solubility of MSH-R-IF (trifluoroacetate salt) in water is approximately 1 mg/ml. We do not recommend storing the aqueous solution for more than one day.

Description

MSH-R-IF is a hypothalamic tripeptide that binds to rat striatum (K_d = 4.69 nM) and has diverse biological activities.¹⁻⁴ In vivo, MSH-R-IF (0.1 mg/kg) decreases immobility of mice in the forced swim test, indicating antidepressant-like activity.² MSH-R-IF (20 mg/kg) increases striatal concentration of dopamine (Item No. 21992) and the dopamine metabolites DOPAC, 3-methoxy tyramine (3-MT; Item No. 20511), and homovanillic acid (HVA) in a mouse model of Parkinson's disease induced by MPTP.³ It decreases vacuous chewing movements induced by haloperidol (Item No. 12014) in a rat model of tardive dyskinesia when administered at a dose of 2 mg/kg.⁴ MSH-R-IF also has anti-opiate effects, reversing analgesia induced by morphine (Item No. ISO60147) and an enkephalin in mice in a radiant heat tail-flick assay.¹

References

- 1. Pan, W. and Kastin, A.J. From MIF-1 to endomorphin: The Tyr-MIF-1 family of peptides. Peptides 28(12), 2411-2434 (2007).
- 2. Kastin, A.J., Abel, D.A., Ehrensing, R.H., et al. Tyr-MIF-1 and MIF-1 are active in the water wheel test for antidepressant drugs. Pharmacol. Biochem. Behav. 21(5), 767-771 (1984).
- 3. Marcotte, E.R., Chugh, A., Mishra, R.K., et al. Protection against MPTP treatment by an analog of Pro-Leu-Gly-NH₂ (PLG, MIF-1). Peptides **19(2)**, 403-406 (1998).
- 4. Sharma, S., Paladino, P., Gabriele, J., et al. Pro-Leu-glycinamide and its peptidomimetic, PAOPA, attenuate haloperidol induced vacuous chewing movements in rat: A model of human tardive dyskinesia. Peptides 24(2), 313-319 (2003).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFFTY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

uyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/01/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM